Roy Vagelos is retiring and leaving a legacy of leadership lessons

The longtime pharma leader is stepping down from his role as chair of Regeneron’s board in June after decades in drug development. 

By Karissa Waddick • April 25, 2023

Tuberculosis is the world’s deadliest infectious disease — and treatments remain underfunded

Tuberculosis control and funding lost 20 years of progress during the COVID-19 pandemic, but scientists and world health groups are still plugging away.

By Alexandra Pecci • April 24, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

20 years on, the next stage of the human genome revolution is brewing

Two decades after the Human Genome Project, scientists are on the brink of uncovering its full potential for drug development.

By Karissa Waddick • April 24, 2023

A physician’s perspective on health equity, diversity and inclusion

Dr. Preeti Parikh sees parallels between promoting health equity and current DE&I challenges in the workplace.

By Preeti Parikh, MD, Executive Medical Director, GoodRx • April 24, 2023

The 99 seconds that changed this CEO’s life

Peter Kirk’s marathon story of inspiration and perseverance.

By Taren Grom • April 21, 2023

Cure Ventures has $350M to pour deep into biotech ‘company building’

The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.

By Michael Gibney • April 20, 2023

Depression has long been treated chronically — Sage wants to change that

Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

By Michael Gibney • April 18, 2023

Patient influencers are here to stay — where are the regulations?

As social media health influencers enter the world of pharma advertising, experts warn that more guardrails are needed to protect the industry and patients.

By Karissa Waddick • April 17, 2023

A new era of COVID innovation is here

With a $5 billion dollar infusion, a new White House program is helping catalyze development of next-gen treatments, from pan-coronavirus vaccines to enhanced antivirals. 

By Kelly Bilodeau • April 17, 2023

Overcoming Analytical Challenges for Gene Therapies

Gain a deep understanding of the analytical challenges that gene therapy developers face, and how a strategic partnership with a specialized CRO can offer a competitive advantage in accelerating timelines and improving program success.

By Jennifer Chadwick, Ph.D. | Chief Scientific Officer of ProtaGene • April 17, 2023

Fighting vaccine hesitancy may require a new approach from pharma

The COVID-19 pandemic highlighted an ongoing problem of vaccine hesitancy undermining public health efforts. One way pharmas can help is to change the narrative.

By Michael Gibney • April 13, 2023

Woman of the Week: uMotif’s Julia Lakeland

The chief product officer’s work in transforming clinical trial technology is driven by people.

By Taren Grom • April 12, 2023

What’s pharma doing wrong to improve trial diversity? ‘Everything’

Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.

By Karissa Waddick • April 12, 2023

He helped launch the Pfizer COVID vaccine — now this startup CEO is hunting a lingering pandemic foe

All of the COVID-19 mAbs have been pulled from the market. But Dave Hering, CEO of Invivyd, hopes to change that.

By Meagan Parrish • April 11, 2023

After working at Merck during the Vioxx scandal, this former sales rep is on a mission to fix the system

The founder and CEO for the Accreditation Council for Medical Affairs is increasing accountability in pharma by emphasizing training, standards and ethics in medical affairs.

By Alexandra Pecci • April 11, 2023

GoodRx Health is the one-stop-shop for patients — and marketers

Optimize patient conversion through a single platform with GoodRx: the one-stop-shop for patients — and marketers.

April 10, 2023

5 minutes with — Parexel’s Peyton Howell

The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."

By Taren Grom • April 7, 2023

Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

Although Janssen bowed out of the RSV vaccine race, several pharmas are quickly closing in on the finish line in a disease with decades of unmet need.

By Michael Gibney • April 6, 2023

Amgen’s aim for a ‘moonshot’ in cardiovascular disease

A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.  

By Taren Grom • April 5, 2023

Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Dr. Theresa Heah has spent her entire career moving ophthalm...

By Taren Grom • April 5, 2023

All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023

Staff shortages cause slowdowns in booming cell and gene therapy market

New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.

By Karissa Waddick • April 3, 2023

Leaders wave a magic wand at pharma’s thorniest issues

The major challenges pharma leaders would solve with a quick flick of an imaginary wand.

By PharmaVoice staff • March 31, 2023

Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

By Michael Gibney • March 30, 2023

Pharma’s salesforce is suffering — what does version 2.0 look like?

Ahead of turbulent market conditions, an industry markets leader encourages companies to rethink their sales strategy.

By Kelly Bilodeau • March 28, 2023